GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » Other Net Income (Loss)

PARNF (Parnell Pharmaceuticals Holdings) Other Net Income (Loss) : $-0.00 Mil (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings Other Net Income (Loss)?

Parnell Pharmaceuticals Holdings's Other Net Income (Loss) for the six months ended in Dec. 2018 was $-0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.00 Mil.

Parnell Pharmaceuticals Holdings's quarterly Other Net Income (Loss) increased from Dec. 2016 ($-0.00 Mil) to Dec. 2017 ($0.00 Mil) but then declined from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($-0.00 Mil).

Parnell Pharmaceuticals Holdings's annual Other Net Income (Loss) increased from Dec. 2016 ($-0.00 Mil) to Dec. 2017 ($0.00 Mil) but then declined from Dec. 2017 ($0.00 Mil) to Dec. 2018 ($-0.00 Mil).


Parnell Pharmaceuticals Holdings Other Net Income (Loss) Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings Other Net Income (Loss) Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Other Net Income (Loss)
Get a 7-Day Free Trial - - - - -

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
Other Net Income (Loss) Get a 7-Day Free Trial - - - - -

Parnell Pharmaceuticals Holdings Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.